Zydus Lifesciences receives USFDA approval for gRevlimidZYDUSLIFE - 635 Change: 5.20 (0.83 %)
News: Zydus Lifesciences has received USFDA final approval to market gRevlimid, in strengths of 5 mg, 10 mg, 15 mg and 25 mg and tentative USFDA approvals for 2.5 mg and 20 mg strength. gRevlimid is used to treat various types of cancers and will be manufactured at the group’s formulation manufacturing facility at the Ahmedabad SEZ.
View: Revlimid capsule in strengths of 5 mg, 10 mg, 15 mg, 25 mg had CY21 annual sales of ~ US$7.825 billion. Natco received approval for these strengths in March, 2022. With loss of exclusivity in September, 2022, many players are ready to enter the US market in this wave of launch. We have factored in the NPV of Rs 27 for gRevlimid opportunity for Zydus Lifesciences. Additionally, Zydus Life has guided for 30+ launches in the US. We expect the US business (ex-gRevlimid) to grow at 9% CAGR to Rs 6885 crore in FY22-24E.